Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD

Blood (2019) 134 (Supplement_1): 5268.

https://doi.org/10.1182/blood-2019-123466

Published: 2019

Journal Articles

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Blood (2016) 128 (22): 1102.

https://doi.org/10.1182/blood.V128.22.1102.1102

Published: 2016

Journal Articles

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Robert E Marcus, Andrew J Davies, FRCP PhD, Kiyoshi Ando, Wolfram Klapper, MD, Stephen Opat, MD, Carolyn J Owen, Elizabeth H Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour, William Townsend, Marek Trněný, Michael K Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann, MD

Blood (2016) 128 (22): 6.

https://doi.org/10.1182/blood.V128.22.6.6

Published: 2016

Journal Articles

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

Christiane Pott, Eva Hoster, PhD, Britta Kehden, Michael Unterhalt, PhD, Michael Herold, Richard H van der Jagt, Ann Janssens, MD, Michael Kneba, Jiri Mayer, MD, Chris Pocock, PhD FRCPath FRCP, Nathalie Danesi, PhD, Günter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Robert E Marcus, Wolfgang Hiddemann

Blood (2016) 128 (22): 613.

https://doi.org/10.1182/blood.V128.22.613.613

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population

Anjum Bashir Khan, MBChB, MRCP, Alesia Abigael Hunt, MBChB, Victoria T Potter, MD FRCPA, FRACP, Shireen Kassam, MBBS, Deborah Yallop, MB, BS, BSc.(hons), MRCP, FRCPath, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, MD PhD FRCPath, Ghulam Mufti, MD DM, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Robert E. Marcus, MBBS, FRCP, FRCPath

Blood (2014) 124 (21): 1197.

https://doi.org/10.1182/blood.V124.21.1197.1197

Published: 2014

Journal Articles

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Kirit M Ardeshna, MD, Peter Hoskin, Paul Smith, PhD, Nicholas Chadwick, Nivette Braganca, Wai-Lup Wong, MD, Irfan Kayani, Bal Sanghera, Patricia Diez, Helen Lucraft, Andrew Jack, PhD, MB, Christopher J McNamara, George Mikhaeel, MD, Scott Marshall, MD, Ruth Pettengell, Robert E. Marcus, MBBS, FRCP, FRCPath, Anton Kruger, David C Linch, MD FMedSci

Blood (2012) 120 (21): 1621.

https://doi.org/10.1182/blood.V120.21.1621.1621

Published: 2012

Journal Articles

Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML.

Pramila Krishnamurthy, MA MRCP FRCPath, Victoria T Potter, MBBS, FRCPA, FRACP, Austin G Kulasekararaj, Victor Noriega, Hugues de Lavallade, Robin M. Ireland, FRCP, FRCPath, Stephen Devereux, FRCP, FRCPath, Judith C. W. Marsh, MD, PhD, Robert E. Marcus, MBBS, FRCP, FRCPath, Barbara Czepulkowski, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 3141.

https://doi.org/10.1182/blood.V120.21.3141.3141

Published: 2012

Journal Articles

Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed Advanced Stage Follicular Lymphoma

Victor Noriega, MD, Anjum Bashir Khan, MBChB, MRCP, Stephen Devereux, FRCP, FRCPath, PhD, Robert E. Marcus, MBBS, FRCP, FRCPath, Michelle Kenyon, Victoria T Potter, MBBS, FRCPA, FRACP, Ghulam J Mufti, FRCP, FRCPath, M.D., Antonio Pagliuca, MBBS, FRCP, FRCPath, MA

Blood (2012) 120 (21): 2022.

https://doi.org/10.1182/blood.V120.21.2022.2022

Published: 2012

Journal Articles

HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS

Victor Noriega, MD, Hugues de Lavallade, MD, Victoria T Potter, MBBS, FRCPA, FRACP, Pramila Krishnamurthy, Judith C. W. Marsh, Prof MD PhD, Stephen Devereux, FRCP, FRCPath, Ph.D., Robert E. Marcus, MBBS, FRCP, FRCPath, Kavita Raj, Donal McLornan, MD, PhD, Anjum Bashir Khan, MBChB, MRCP, Sangeeta Atwal, MBBS MRCP FRCPath, Robin M. Ireland, FRCP, FRCPath, Deborah Yallop, BSc, FRCPath, MB, BS, MRCP, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J Mufti, FRCP, FRCPath, M.D.

Blood (2012) 120 (21): 4158.

https://doi.org/10.1182/blood.V120.21.4158.4158

Published: 2012

Journal Articles

Long-Term Outcomes of Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation (RIC-HSCT) for AML with Myelodysplasia-Related Changes

Victoria T Potter, MBBS, FRCPA, FRACP, Pramila Krishnamurthy, ZiYi Lim, Victoria J Tindell, MBChB FRCPath, Stephen Devereux, FRCP, FRCPath, PhD, Robert E. Marcus, MBBS, FRCP, FRCPath, Robin M. Ireland, FRCP, FRCPath, Judith C. W. Marsh, Prof MD PhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2011) 118 (21): 3079.

https://doi.org/10.1182/blood.V118.21.3079.3079

Published: 2011

Journal Articles

Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

John Radford, MD, Andrew Davies, Guillaume Cartron, MD, PhD, Franck Morschhauser, MD, PhD, Gilles Andre Salles, Robert E. Marcus, MBBS, FRCP, FRCPath, Michael K. Wenger, Elina Asikanius, Elisabeth Wassner-Fritsch, Umberto Vitolo, MD

Blood (2011) 118 (21): 270.

https://doi.org/10.1182/blood.V118.21.270.270

Published: 2011

Journal Articles

HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,

Silvia Montoto, MD, Kate Shaw, Jessica Okosun, Shreyans Gandhi, Paul Fields, MD, PhD, Andrew Wilson, Milensu Shanyinde, Kate Cwynarski, Robert E. Marcus, MBBS, FRCP, FRCPath, Johannes de Vos, Anna Marie Young, Melinda Tenant-Flowers, FRCP MSc, Chloe Orkin, Margaret Johnson, Daniella Chilton, John G. Gribben, MD, DSc, Mark Bower, MD

Blood (2011) 118 (21): 3646.

https://doi.org/10.1182/blood.V118.21.3646.3646

Published: 2011

Journal Articles

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, Liliana Baila, MD, Livia Giurgia, Richard Klasa, Robert E Marcus, Max Wolf, Eva Kimby, Anton Hagenbeek

Blood (2008) 112 (11): 836.

https://doi.org/10.1182/blood.V112.11.836.836

Published: 2008

Journal Articles

Clinicopathological Analysis of 32 Cases of Extra-Medullary Myeloid Tumour.

Tony Todd, Martin W. Besser, Jenny I. Craig, Robert E. Marcus

Blood (2007) 110 (11): 4317.

https://doi.org/10.1182/blood.V110.11.4317.4317

Published: 2007

Journal Articles

BCL-2/IgH PCR Values at the End of Induction Treatment Are Not Predictive for Progression Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized Phase III Intergroup Trial.

Bert A. van der Reijden, PhD, Marinus H.J Van Oers, MD.PhD, Evelyn Tonissen, Martine Van Glabbeke, PhD, Livia Giurgia, Richard Klasa, MD.PhD, Robert E. Marcus, MD.PhD, Max Wolf, MD.PhD, Mars Van t Veer, MD.PhD, Andrej Vranovsky, MD, Harald Holte, MD, Eva Kimby, MD, Anton Hagenbeek, MD.PhD

Blood (2007) 110 (11): 791.

https://doi.org/10.1182/blood.V110.11.791.791

Published: 2007

Journal Articles

The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK.

Gavin Lewis, MSc, Robert E. Marcus, MB, Stephen J. Proctor, FRCP FRCPath, Marlene Gyldmark, James Creeden, MD PhD, Rick Aultman, MSc, Fred Jost, MSc

Blood (2006) 108 (11): 345.

https://doi.org/10.1182/blood.V108.11.345.345

Published: 2006

Journal Articles

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

Robert E. Marcus, MB, Philippe Solal-Celigny, MD, Kevin Imrie, MD, FRCPC, John V. Catalano, MD, Anna Dmoszynska, MD, PHD, João C. Raposo, MD, Fritz C. Offner, MD, PHD, José Gomez-Codina, MD, PHD

Blood (2006) 108 (11): 481.

https://doi.org/10.1182/blood.V108.11.481.481

Published: 2006

Journal Articles

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Marinus H. J. van Oers, Richard Klasa, Robert E. Marcus, Max Wolf, Eva Kimby, Randy D. Gascoyne, Andrew Jack, Mars van't Veer, Andrej Vranovsky, Harald Holte, Martine van Glabbeke, Ivana Teodorovic, Cynthia Rozewicz, Anton Hagenbeek

Blood (2006) 108 (10): 3295–3301.

https://doi.org/10.1182/blood-2006-05-021113

Published: 2006

Journal Articles

Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial.

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, PhD, Ivana Teodorovic, MD, Cynthia Rozewicz, Richard Klasa, MD, Robert E. Marcus, MD, Max Wolf, MD, Eva Kimby, MD, Anton Hagenbeek, MD, PhD

Blood (2005) 106 (11): 353.

https://doi.org/10.1182/blood.V106.11.353.353

Published: 2005

NARROW

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study

Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML.

Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed Advanced Stage Follicular Lymphoma

HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS

Long-Term Outcomes of Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation (RIC-HSCT) for AML with Myelodysplasia-Related Changes

Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Clinicopathological Analysis of 32 Cases of Extra-Medullary Myeloid Tumour.

BCL-2/IgH PCR Values at the End of Induction Treatment Are Not Predictive for Progression Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized Phase III Intergroup Trial.

The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK.

MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only